ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) Price, Holdings, & News

ETF Overview

Zenas BioPharma Inc. is a clinical-stage global biopharmaceutical company. It involved in the development and commercialization of transformative immunology-based therapies for patients in need. The company's lead product candidate includes obexelimab and Fc?RIIb. Zenas BioPharma Inc. is based in WALTHAM, Mass.

Key Stats

• Today's Range: $9.31 to $10.38
• 50-Day Range: $10.02 to $10.09
• 52-Week Range: $8.28 to $18.64
• Volume: 3.63 million shs
• Average Volume: 364,207 shs
• Market Capitalization: $418.32 million
• Assets Under Management: $2.85 million
• Dividend Yield: N/A
• Net Expense Ratio: 0.95%
• Aggregate Rating: N/A

ZBIO ETF - Frequently Asked Questions

How were ProShares UltraPro Short Nasdaq Biotechnology's earnings last quarter?

ProShares UltraPro Short Nasdaq Biotechnology (NASDAQ:ZBIO) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($5.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($13.00) by $7.98.

When did ProShares UltraPro Short Nasdaq Biotechnology IPO?

ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) raised $225 million in an IPO on Friday, September 13th 2024. The company issued 13,235,294 shares at a price of $17.00 per share.

When did the company's quiet period expire?

ProShares UltraPro Short Nasdaq Biotechnology's quiet period expired on Wednesday, October 23rd. ProShares UltraPro Short Nasdaq Biotechnology had issued 13,235,294 shares in its initial public offering on September 13th. The total size of the offering was $224,999,998 based on an initial share price of $17.00. During the company's quiet period, insiders and underwriters that worked on the IPO were restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

What other stocks do shareholders of ProShares UltraPro Short Nasdaq Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ProShares UltraPro Short Nasdaq Biotechnology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), BioSig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI).

Fund Details

• Issuer: ProShares
• Fund Name: ProShares UltraPro Short Nasdaq Biotechnology
• Tax Classification: Regulated Investment Company
• Stock Exchange: NASDAQ
• Current Symbol: NASDAQ:ZBIO
• Inception Date: 6/22/2015
• Fund Manager: Michael Neches, Tarak Dave
• Web: www.zenasbio.com
• Phone: 857-271-2954

Fund Focus

• Asset Class: Equity
• Benchmark: NASDAQ Biotechnology Index
• Category: Sector
• Focus: Health Care
• Development Level: Developed Markets
• Region: North America
• Number of Holdings: 0

Fund Statistics

• Assets Under Management: $2.85 million
• Average Daily Volume: $25,501.70
• Discount/Premium: 0.00%

Administrator, Advisor and Custodian

• Administrator: J.P. Morgan Investor Services Co.
• Advisor: ProShare Advisors LLC
• Custodian: JPMorgan Chase Bank, N.A.
• Distributor: SEI Investments Distribution Co.
• Transfer Agent: JPMorgan Chase Bank, N.A.
• Trustee: N/A
• Lead Market Maker: Virtu Financial

Miscellaneous

• Outstanding Shares: 41,790,000
• Beta: N/A